CURE Pharmaceutical Completes $20 Million Acquisition of Sera Labs, a Leading Health, Wellness and Beauty Brand Marketing and Multi-Channel Distribution Platform Company
Summary
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. “Our acquisition of Sera Labs has been validated over the last few months as we have seen a strong cultural fit and expanded opportunities including a pivot to tele-wellness through which we will deliver to consumers science-based products that meet their personalized wellness objectives,” said Rob Davidson, CURE Pharmaceutical CEO. With Sera Labs’ expertise in brand marketing and multi-channel distribution platform, we can now give consumers greater access to the dosage forms and drug delivery technologies they seek. With the consummation of the transaction, the Sera Labs’ team is excited to introduce consumers to CURE’s innovative delivery system, which we believe will change the way they take daily nutraceuticals. Strategically positioned in the growth market categories of beauty, health & wellness, and pet care, Sera Labs products are sold in major national drug store, grocery chains and mass retailers.